Bicycle Therapeutics plc Deferred Income Tax Expense (Benefit)
Bicycle Therapeutics plc (BCYC) reported Deferred Income Tax Expense (Benefit) of $85.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-07-30
- Bicycle Therapeutics plc deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $326.00K.
- Bicycle Therapeutics plc deferred income tax expense (benefit) for the quarter ending 2026-03-31 was -$241.00K.
- Bicycle Therapeutics plc deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $843.00K.
- Bicycle Therapeutics plc deferred income tax expense (benefit) for the quarter ending 2025-09-30 was -$46.00K.
- Bicycle Therapeutics plc deferred income tax expense (benefit) for fiscal 2025 was -$850.00K.
- Bicycle Therapeutics plc deferred income tax expense (benefit) for fiscal 2024 was -$5.23M, a 258.08% decline from fiscal 2023.
- Bicycle Therapeutics plc deferred income tax expense (benefit) for fiscal 2023 was $3.31M.
- Bicycle Therapeutics plc deferred income tax expense (benefit) for fiscal 2022 was -$4.98M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $326.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $85.00K 10-Q · filed 2026-07-30 | $928.00K derived: sum of 3 quarters · filed 2026-07-30 | $882.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$241.00K 10-Q · filed 2026-04-30 | $602.00K derived: sum of 2 quarters · filed 2026-04-30 | $556.00K derived: sum of 3 quarters · filed 2026-04-30 | $225.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $843.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $797.00K derived: sum of 2 quarters · filed 2026-03-17 | $466.00K derived: sum of 3 quarters · filed 2026-07-30 | -$850.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | -$46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$377.00K derived: sum of 2 quarters · filed 2026-07-30 | -$1.69M 10-Q · filed 2025-10-30 | -$2.73M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$1.65M 10-Q · filed 2026-07-30 | -$2.68M derived: sum of 3 quarters · filed 2026-07-30 | -$6.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$1.32M 10-Q · filed 2026-04-30 | -$2.35M derived: sum of 2 quarters · filed 2026-04-30 | -$5.67M derived: sum of 3 quarters · filed 2026-04-30 | -$5.78M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$4.35M derived: sum of 2 quarters · filed 2026-03-17 | -$4.46M derived: sum of 3 quarters · filed 2026-03-17 | -$5.23M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$3.42M derived: sum of 2 quarters · filed 2025-10-30 | -$4.19M 10-Q · filed 2025-10-30 | -$4.47M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | -$110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$877.00K 10-Q · filed 2025-08-08 | -$1.16M derived: sum of 3 quarters · filed 2026-03-17 | $6.11M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | -$767.00K 10-Q · filed 2025-05-01 | -$1.05M derived: sum of 2 quarters · filed 2026-03-17 | $6.22M derived: sum of 3 quarters · filed 2026-03-17 | $4.64M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$282.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $6.99M derived: sum of 2 quarters · filed 2026-03-17 | $5.41M derived: sum of 3 quarters · filed 2026-03-17 | $3.31M 10-K · filed 2026-03-17 |
| 2023-09-30 | $7.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $5.69M derived: sum of 2 quarters · filed 2024-10-31 | $3.59M 10-Q · filed 2024-10-31 | $1.25M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$3.68M 10-Q · filed 2024-08-06 | -$6.02M derived: sum of 3 quarters · filed 2025-02-25 | -$7.04M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$2.11M 10-Q · filed 2024-05-02 | -$4.44M derived: sum of 2 quarters · filed 2025-02-25 | -$5.47M derived: sum of 3 quarters · filed 2025-02-25 | -$6.33M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$3.36M derived: sum of 2 quarters · filed 2025-02-25 | -$4.23M derived: sum of 3 quarters · filed 2025-02-25 | -$4.98M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$1.89M derived: sum of 2 quarters · filed 2023-11-02 | -$2.64M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | -$868.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$1.62M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | -$748.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$1.67M 10-K · filed 2024-02-20 | |||
| 2020-12-31 | -$673.00K 10-K · filed 2023-02-28 | |||
| 2019-12-31 | -$364.00K 10-K · filed 2022-03-01 | |||
| 2018-12-31 | -$378.00K 10-K · filed 2021-03-11 | |||
| 2017-12-31 | -$108.00K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |